Form 4: BRYNELSEN CHARLES reports purchase transactions in COCH
Rhea-AI Filing Summary
BRYNELSEN CHARLES reported open-market purchase transactions in a Form 4 filing for COCH. The filing lists transactions totaling 2,600,000 shares at a weighted average price of $0.40 per share. Following the reported transactions, holdings were 600,000 shares.
Positive
- None.
Negative
- None.
Insights
Director makes sizable open‑market share and warrant purchases in Envoy Medical.
Director Charles Brynelsen acquired 1,000,000 Envoy Medical Class A shares at $0.40 plus 1,600,000 warrants with a $0.40 exercise price on 02/12/2026. All are reported as directly owned, meaning they sit in his personal beneficial stake.
The warrants’ exercisability depends on shareholder approval of the underlying shares and include expiration triggers tied to FDA milestones for the Acclaim CI Device. This links part of his upside to both corporate governance actions and regulatory progress. Actual impact on ownership and dilution will depend on future shareholder approvals and warrant exercises.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Warrant (right to buy) | 600,000 | $0.00 | -- |
| Purchase | Warrant (right to buy) | 1,000,000 | $0.00 | -- |
| Purchase | Class A Common Stock | 1,000,000 | $0.40 | $400K |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
Footnotes (1)
- Options to purchase 46,875 shares vest on 10/15/2023, and the remaining 15,625 shares vest pro rata on the 15th of each month thereafter for 36 consecutive months. Exercisable upon shareholder approval of the issuance of shares of Class A Common Stock underlying the warrants. The Series A-1 Warrants expire on the earlier of (i) two years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has submitted a Premarket Approval Application to the Food and Drug Administration (FDA) for its Acclaim CI Device. The Series A-2 Warrants expire on the earlier of (i) five years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has received FDA approval for its Acclaim CI Device.
